MARCO

Across TCGA pan-cancer cohorts, MARCO mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MARCO data layer compared with 23 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MARCO mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MARCO expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where MARCO mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.420	0.763	.004	47	view →
CCRCC	DFS	Median	II,III,IV	0.686	0.217	.011	5	view →
PDAC	DFS	Median	IV	0.245	0.715	.038	4	view →
LSCC	DFS	Median	All	0.896	0.972	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MARCO–LUAD (DFS)

Open the LUAD breakdown →